Propagation and Dissemination Strategies of Transmissible Spongiform Encephalopathy Agents in Mammalian Cells.
Heumüller SE, Hornberger AC, Hebestreit AS, Hossinger A, Vorberg IM.
Int J Mol Sci. 2022 Mar 8;23(6):2909. doi: 10.3390/ijms23062909.
Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist.
Brown P.
Neurology. 2008 Feb 26;70(9):713-22. doi: 10.1212/01.wnl.0000302186.10596.f6.
Working with transmissible spongiform encephalopathy agents.
Brown P, Abee CR.
ILAR J. 2005;46(1):44-52. doi: 10.1093/ilar.46.1.44.
microRNA-146a as a biomarker for transmissible spongiform encephalopathy.
Pogue A, Zhao Y, Lukiw W.
Folia Neuropathol. 2022;60(1):24-34. doi: 10.5114/fn.2022.113561.
Laboratory activities involving transmissible spongiform encephalopathy causing agents: risk assessment and biosafety recommendations in Belgium.
Leunda A, Van Vaerenbergh B, Baldo A, Roels S, Herman P.
Prion. 2013 Sep-Oct;7(5):420-33. doi: 10.4161/pri.26533. Epub 2013 Sep 20.
Prion protein PrP nucleic acid binding and mobilization implicates retroelements as the replicative component of transmissible spongiform encephalopathy.
Lathe R, Darlix JL.
Arch Virol. 2020 Mar;165(3):535-556. doi: 10.1007/s00705-020-04529-2. Epub 2020 Feb 5.
Resistance of transmissible spongiform encephalopathy agents to decontamination.
Taylor DM.
Contrib Microbiol. 2001;7:58-67. doi: 10.1159/000060376.
Prion Diseases.
Whitechurch BC, Welton JM, Collins SJ, Lawson VA.
Adv Neurobiol. 2017;15:335-364. doi: 10.1007/978-3-319-57193-5_13.
[Transmissible spongiform encephalopathy].
Koukolík F.
Cas Lek Cesk. 1998 Apr 20;137(8):227-30.
Transmissible spongiform encephalopathy update and implications for blood safety.
Ricketts MN, Brown P.
Clin Lab Med. 2003 Mar;23(1):129-37. doi: 10.1016/s0272-2712(02)00066-5.
